Our study found that serum anti-14-3-3 zeta autoantibody is a potential non-invasive serum biomarker for predicting hepatocarcinogenesis, which might significantly improve the diagnosis efficiency for early and AFP-negative liver cancer and reduce the associated fatality rate to a certain extent. This evidence concerns the gene AFP and liver cancer.